The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyramidal Movement Disorders

Archives of Internal Medicine

Volumn 153, Issue 12, 1993, Pages 1469-1475

  Ganzini, Linda ^a   Casey, Daniel E ^a   Hoffman, William F ^a   Mccall, Anthony L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDIAZEPOXIDE; INSULIN; METOCLOPRAMIDE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; STOMACH PARESIS; TARDIVE DYSKINESIA;

ADULT; AGED; AGED, 80 AND OVER; AKATHISIA, DRUG-INDUCED; BASAL GANGLIA DISEASES; DIABETES MELLITUS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMAN; MALE; METOCLOPRAMIDE; MIDDLE AGE; PARKINSON DISEASE, SECONDARY; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027233025     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1993.00410120051007     Document Type: Article

References (30)

1. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98:86-95.
2. Casey DE. Metoclopramide side effects. Ann Intern Med. 1983;98:673-674.
3. Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med. 1989;149:2486-2492.
4. Orme ML’E, Tallic RC. Metoclopramide and tardive dyskinesia in the elderly. BMJ. 1984;289:397-398.
5. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126:23-25.
6. Wiholm BE, Mortimer O, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. BMJ. 1984;288:545-547.
7. Ganzini L, Heintz RT, Hoffman WF, Keepers G, Casey DE. Acute extrapyramidal syndromes in neuroleptic-treated elderly: a pilot study. J Geriatr Psychiatry Neurol. 1991;4:222-226.
8. Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology. 1989;97:1-11.
9. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry. 1988;145:869-871.
10. American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
11. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery of tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368-1373.
12. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics: a controlled study. Arch Gen Psychiatry. 1991;48:259-263.
13. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide: an updated review of its pharmacologic properties and clinical use. Drugs. 1983;25:451-494.
14. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ. 1985;291:930-932.
15. Physicians’ Desk Reference. 45th ed. Montvale, NJ: Medical Economics Data; 1991.
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare; 1976:534-537.
18. Schooler N, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
19. Gerlach J. Tardive dyskinesia. Dan Med Bull. 1979;25:209-244.
20. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
21. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981.
22. Stevens J. Applied Multivariate Statistics for the Social Scenes. Hillsdale, NJ: Lawrence Erlbaum Associates; 1986.
23. Kramer S. Clinical Epidemiology and Biostatistics. New York, NY: Springer-Verlag NY Inc; 1988.
24. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1983.
25. Bateman DN, Darling WM, Boys R, Rawlins MD. Extrapyramidal reactions to metoclopramide and prochlorperazine. Q J Med. 1989;264:307-311.
26. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987;144:1148-1153.
27. McCall AL. The impact of diabetes on the CNS. Diabetes. 1992;41:557-570.
28. McCall AL. Cerebral microvascular transport and metabolism: implications for diabetes. In: Ruderman N, Williamson J, Brownlee M, eds. Hyperglycemia, Diabetes, and Vascular Disease. New York, NY: Oxford University Press Inc; 1992: 59-106.
29. Waddington JL. Schizophrenia, affective psychoses and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants and the conflict of paradigms. Int Rev Neurobiol. 1989;31:297-353.
30. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35: 841-845.